Side Effects & Safety AOD-9604 has a favorable safety profile supported by clinical trial data: FDA GRAS status: The compound received GRAS status as a food ingredient, reflecting some regulatory safety evaluation, though this is not equivalent to drug safety approval Clinical trial tolerability: Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals generally found AOD-9604 well-tolerated at studied doses Injection site reactions: Minor discomfort with subcutaneous administration Headache and nausea: Reported in some clinical trial subjects No significant metabolic effects: Blood glucose, insulin, HbA1c, and IGF-1 were not significantly altered in clinical studies, which distinguishes it favorably from full GH Long-term safety data for subcutaneous use in the research community context (typically higher and more frequent dosing than clinical trials) is limited
The choice of sport-specific populations should also be considered in future experiments
Through systematic fractionation of human albumin, Pickart and colleagues isolated a small peptide responsible for the difference, eventually identifying it as a three-amino-acid sequence glycine, histidine, and lysine with an unusually strong affinity for binding copper(II) ions
Einat H, Yuan P, Manji HK
Prevention: Follow your provider prescribed titration schedule
Research Applications: Multi-pathway signaling interaction modeling
